【基石药业-B(02616.HK)公布Nofazinlimab治疗肝细胞癌的国际多中心 III期研究的最新进展】智通财经

智通财经
04 Jul
【基石药业-B(02616.HK)公布Nofazinlimab治疗肝细胞癌的国际多中心 III期研究的最新进展】智通财经APP讯,基石药业-B(02616.HK)公布有关CS1003-305研究的最新进展,CS1003-305研究是一项国际多中心、双盲、随机对照的III期注册研究,在全球范围内设有74家研究中心,旨在评估PD-1单抗nofazinlimab(CS1003)联合仑伐替尼对比安慰剂联合仑伐替尼一线治疗不可切除或转移性肝细胞癌(HCC)患者的有效性和安全性。该研究的主要终点为总生存期(OS)。关键次要终点包括盲态独立中心审阅(BICR)评估的无进展生存期(PFS)和客观缓解率(ORR)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10